Home  »  Companies   »  Here’s Our Rant About Inovio Pharmaceuticals...

Here’s Our Rant About Inovio Pharmaceuticals Inc. (INO)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Inovio Pharmaceuticals Inc. (NASDAQ:INO) went up by 1.87% from its latest closing price compared to the recent 1-year high of $19.00. The company’s stock price has collected -2.59% of loss in the last five trading sessions. Press Release reported on 12/14/21 that INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18

Is It Worth Investing in Inovio Pharmaceuticals Inc. (NASDAQ :INO) Right Now?

Plus, the 36-month beta value for INO is at 0.51. Opinions of the stock are interesting as 3 analysts out of 9 who provided ratings for Inovio Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $13.63, which is $8.73 above the current price. INO currently public float of 206.92M and currently shorts hold a 21.17% ratio of that float. Today, the average trading volume of INO was 4.27M shares.

INO’s Market Performance

INO stocks went down by -2.59% for the week, with a monthly drop of -19.04% and a quarterly performance of -29.34%, while its annual performance rate touched -46.26%. The volatility ratio for the week stands at 7.01% while the volatility levels for the past 30 days are set at 6.14% for Inovio Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -11.47% for INO stocks with a simple moving average of -35.78% for the last 200 days.

Analysts’ Opinion of INO

Many brokerage firms have already submitted their reports for INO stocks, with Jefferies repeating the rating for INO by listing it as a “Hold.” The predicted price for INO in the upcoming period, according to Jefferies is $6 based on the research report published on December 29th of the previous year 2021.

BofA Securities, on the other hand, stated in their research note that they expect to see INO reach a price target of $8, previously predicting the price at $9. The rating they have provided for INO stocks is “Underperform” according to the report published on September 10th, 2021.

Jefferies gave a rating of “Hold” to INO, setting the target price at $9 in the report published on June 24th of the previous year.

INO Trading at -23.43% from the 50-Day Moving Average

After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.26% of loss for the given period.

Volatility was left at 6.14%, however, over the last 30 days, the volatility rate increased by 7.01%, as shares sank -20.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.51% lower at present.

During the last 5 trading sessions, INO fell by -2.59%, which changed the moving average for the period of 200-days by -45.91% in comparison to the 20-day moving average, which settled at $5.46. In addition, Inovio Pharmaceuticals Inc. saw -2.00% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at INO starting from Zoth Lota S., who sale 961 shares at the price of $5.01 back on Jan 05. After this action, Zoth Lota S. now owns 25,016 shares of Inovio Pharmaceuticals Inc., valued at $4,815 using the latest closing price.

Humeau Laurent, the Chief Scientific Officer of Inovio Pharmaceuticals Inc., sale 10,317 shares at $9.15 during a trade that took place back on Aug 09, which means that Humeau Laurent is holding 68,587 shares at $94,401 based on the most recent closing price.

Stock Fundamentals for INO

Current profitability levels for the company are sitting at:

  • -1760.60 for the present operating margin

The net margin for Inovio Pharmaceuticals Inc. stands at -2245.39. The total capital return value is set at -43.13, while invested capital returns managed to touch -55.59. Equity return is now at value -44.10, with -38.10 for asset returns.

Based on Inovio Pharmaceuticals Inc. (INO), the company’s capital structure generated 8.47 points at debt to equity in total, while total debt to capital is 7.81. Total debt to assets is 7.18, with long-term debt to equity ratio resting at 7.96. Finally, the long-term debt to capital ratio is 7.34.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 97.77, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 0.70 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.30.

Leave a Comment

Your email address will not be published. Required fields are marked *

Is American Express Company (AXP) a Keeper?

American Express Company (NYSE:AXP) went up by 6.66% from its latest closing price compared to the recent 1-year high of $189.03. The company’s stock price




Download Free eBook For


100% free. stop anytime no spam